Save Product
Product Details
Synonyms
IL-17E, IL-25, Interleukin-25
Source
Human IL-17E, His Tag (IL5-H52H9) is expressed from human 293 cells (HEK293). It contains AA Tyr 33 - Gly 177 (Accession # NP_073626.1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 18.8 kDa. The protein migrates as 20-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human IL-17E, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Human IL-17E, His Tag (Cat. No. IL5-H52H9) is more than 95% and the molecular weight of this protein is around 50-75 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human IL-17 RB, Fc Tag (Cat. No. ILB-H5251) at 5 μg/mL (100 μL/well) can bind Human IL-17E, His Tag (Cat. No. IL5-H52H9) with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Interleukin-25
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
1 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
